SS 28 - Lung 2: Novel Lung Cancer Investigations

Moderator(s)

• 

  Charles Simone, MD, FASTRO

  New York Proton Center and Memorial Sloan Kettering Cancer Center
  New York, NY, United States
• 

  David Kozono, MD, PhD

  Dana-Farber/Brigham and Women's Cancer Center
  Boston, MA, United States

Presentations:

• 8:00 AM – 8:10 AM ET

  Risk Factors Correlated with Brain Metastases Risk in Limited-Stage Small Cell Lung Cancer
  

  Presenter: Li Li, MD, PhD, RT – Shandong Cancer Hospital and Institute
• 8:10 AM – 8:20 AM ET

  Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small
  

  Presenter: Aaron Seo, MD, PhD – MD Anderson Cancer Center
• 8:20 AM – 8:30 AM ET

  Phase I Trial of Concurrent Talazoparib and Consolidative Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
  

  Presenter: Benjamin Lok, MD – Princess Margaret Cancer Centre
• 8:30 AM – 8:40 AM ET

  Consolidative Stereotactic Radiotherapy in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer Receiving First-Line Third-Generation EGFR Tyrosine Kinase Inhibitors: A Prospective Phase II Trial
  

  Presenter: Yue Zhou, MD – Fudan University
• 8:40 AM – 8:50 AM ET

  A Phase II Trial of Stereotactic Body Radiotherapy (SBRT) in Patients with Stage IV Oncogene-Driven Non-Small Cell Lung Cancer (NSCLC)
  

  Presenter: Florence Keane, MD – Massachusetts General Hospital
• 8:50 AM – 9:00 AM ET

  External Validation of Oligometastatic Genomic Signature in Non-Small Cell Lung Cancer Patients
  

  Presenter: Ariel Choi, MD – Wake Forest Baptist Medical Center